Efficacy
and safety of glucokinase activators for type 2 diabetes mellitus
therapy: A meta-analysis of double-blind randomizedcontrolled trials
Yiqian Qu 1, Keer Wang1, Shuyuan
Lin, Lingyong Cao*, Zhenghao Xu*
College of Basic Medical Science, Zhejiang Chinese Medical University,
Hangzhou 310053, Zhejiang, China
1 These authors contributed to this work equally.
*Corresponding author:
Lingyong Cao, MD
Binwen Road 548, Hangzhou, Zhejiang, China
Tel & fax: +86-571-86613587, e-mail: caolingyong@163.com (L. Cao)
Zhenghao Xu, PhD
Binwen Road 548, Hangzhou, Zhejiang, China
Tel & fax: +86-571-86613587, e-mail: xuzhenghao@zcmu.edu.cn (Z. Xu)
Abstract
Objectives: To assess the
efficacy and safety of oral glucokinase activator (GKA) in the treatment
of type 2 diabetes mellitus(T2DM).
Methods: We searched PubMed, ClinicalTrails, Cochrane Library,
Web of Science, and CNKI and collected randomized controlled trials
(RCTs) of glucokinase activator in the treatment of T2DM. Revman5.3
software was used to do the meta-analysis. And the risk of bias in the
included RCTs was evaluated according to the Cochrane tool.
Results: Seven double-blind RTCs were included in the final
analysis, with a total of 762 patients. Regarding the efficacy, GKAs
significantly reduced fasting blood glucose (FPG) (mean difference
-0.71, 95% CI: -1.11 to -0.31, based on 459 patients from 5
literatures), and glycated hemoglobin (HbA1c) also significantly reduced
(mean difference: -0.65%, 95% CI: -0.82 to -0.48, based on 570
patients from 4 literatures). Regarding safety, GKAs did not affect the
total rate of adverse events(AEs) (relative risk(RR) 1.11, 95% CI: 0.95
to 1.30, P = 0.19), but increased the risk of hypoglycemia (RR 1.81,
95% CI: 1.35 to 2.42, P < 0.0001). And the risk of diarrhea
(RR 1.59, 95% CI: 0.7 to 3.65, P = 0.26), headache (RR 0.96, 95% CI:
0.41-2.21, P = 0.60) and nausea (RR 2.23, 95% CI: 0.55-9.12, P = 0.24)
were not significantly increased in GKAs group.
Conclusions:Oral
GKAs combined with metformin has an obvious hypoglycemic effect on T2DM
and good tolerance. Further clinical studies are still necessary to
explore its long-term efficacy and safety.
PROSPERO registration: CRD42020188517
Keywords: Glucokinase; Glucokinase activator; Type 2 diabetes;
Meta-analysis